December 15, 2023
JCR Pharmaceuticals said on December 14 that the US FDA has granted orphan drug designation to JR-441, an enzyme therapy for mucopolysaccharidosis type III A (MPS IIIA), also known as Sanfilippo syndrome type A. The FDA designation comes after the...read more